Search clinical trials for: renally impaired subjects

Total 18642 results

USWM, LLC (dba US WorldMeds)
National Institute on Drug Abuse (NIDA)

Completed

Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects

Renally Impaired Subjects

United States
GlaxoSmithKline

Completed

A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.

Diabetes Mellitus, Type 2

United States, South Africa
Boehringer Ingelheim

Completed

Afatinib in Subjects With Kidney Dysfunction

Renal Insufficiency

Germany
Otsuka Pharmaceutical Development & Commercialization...

Completed

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

Schizophrenia | Psychiatric Disorders

United States
Achaogen, Inc.
Department of Health and Human Services

Completed

PK Study of ACHN-490 Injection in Renally Impaired Subjects

Renal Insufficiency
AstraZeneca

Completed

Renal Impairment Study

Reflux | Renal Excretion

Sweden
AstraZeneca

Completed

Safety Study of AZD5672 in Renally Impaired Subjects

Renal Impairment

Germany
Cassava Sciences, Inc.

Not yet recruiting

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

Hepatic Insufficiency
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects

Type 2 Diabetes

China
Fujian Akeylink Biotechnology Co., Ltd.

Recruiting

Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function

COVID-19 Pneumonia

China
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function

Chronic Kidney Disease
Aphaia Pharma US LLC

Recruiting

A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation (APHD-012) in Subjects With a Pathological Oral Glucose Tolerance Test (OGTT)

PreDiabetes | Glucose Tolerance Impaired

Slovakia
Atea Pharmaceuticals, Inc.

Recruiting

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment | Healthy Volunteer

United States
Atea Pharmaceuticals, Inc.

Recruiting

Study of AT-527 in Subjects With Normal and Impaired Renal Function

Renal Impairment | Healthy Volunteer

Canada
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function

Esophageal Cancer | Advanced Solid Tumor

China
Centre Hospitalier National d'Ophtalmologie des...

Recruiting

Mobility Protocol Adapted for Advanced Visually Impaired Subjects (PROMA)

Pigmentary Retinopathy

France
Sinotau Pharmaceutical Group

Completed

Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects

Alzheimer Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function

Renal Impairment

China
Bausch Health Americas, Inc.

Terminated

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

Severe Hepatic Impairment

United States
Fujian Akeylink Biotechnology Co., Ltd.

Completed

Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver Function

COVID-19 Pneumonia

China
MediBeacon

Completed

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

Acute Kidney Injury

United States
VectivBio AG

Completed

A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

Germany, Slovakia
Daiichi Sankyo, Inc.

Completed

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Hepatic Impairment | Moderate Impaired Hepatic Function

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
University of Missouri-Columbia
Sagimet Biosciences Inc.

Completed

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Metabolic Syndrome

United States
Federal State Budgetary Scientific Institution...
Russian Science Foundation; Group of companies EFKO

Completed

The Influence of Food for Special Dietary Use - Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid on Psychophysiological Functions of Subjects Without Meaningful Organic and Cognitive Pathology (Spread Bogatyr)

Cognitive Change | Emotional Regulation | Concentration Ability Impaired | Memory; Disturbance, Mild

Russian Federation
Bayer

Completed

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

Overactive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic Cough

United States
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (XARENAL)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Hua Medicine Limited

Completed

A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers

Type 2 Diabetes Mellitus

China
Celgene

Completed

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) (POM Renal)

Multiple Myeloma | Renal Impairment

United States, Canada
Genfit

Completed

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

Renal Impairment | Kidney Disease | Renal Disease

United States
Centre Hospitalier Universitaire de Saint Etienne
Ministry of Health, France

Terminated

Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants (VERDICT)

Renal Insufficiency

France
Rocket Pharmaceuticals Inc.
California Institute for Regenerative Medicine (CIRM)

Terminated

A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis

Infantile Malignant Osteopetrosis

United States
Chimerix

Completed

Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

Hepatic Impairment

United States
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Impaired Hepatic Function

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Renal Impairment

Germany, Bulgaria
Maastricht University
AstraZeneca

Completed

Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation (MaasFlex)

Prediabetic State | Substrate Oxidation

Netherlands
Shire

Completed

Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function

Healthy | Hepatic Impairment

United States
Daiichi Sankyo, Inc.

Completed

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Moderate Hepatic Impairment

United States
Shire

Completed

Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function

Impaired Renal Function

United States
University of Iowa

Terminated

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity (REVIVE)

Obesity | Metabolic Syndrome X

United States
Novartis Pharmaceuticals

Completed

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Hepatic Impairment

Germany, Belgium, Lithuania, United States, Bulgaria, Romania
SecuraBio

Completed

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects (IPI-145-14)

Hepatic Impairment

United States
Steno Diabetes Center Copenhagen
University of Copenhagen; University of Aarhus; Herlev and Gentofte Hospital

Completed

The Effect of Curcumin on Liver Fat Content in Obese Subjects

Insulin Resistance | Obesity, Abdominal | Non-Alcoholic Fatty Liver Disease | Glucose Tolerance Impaired

Denmark
Pfizer's Upjohn has merged with Mylan to form Viatris...

Terminated

An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis

PK Properties Of Gabapentin In Subjects With Impaired Renal Function

Japan
Bayer

Completed

Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects

Anemia

Germany
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function

Healthy Subjects | Hepatic Impairment

China
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

Alcoholism | Hepatic Cirrhosis

Germany, Belgium, United States, South Africa
Novartis Pharmaceuticals

Completed

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

Renal Impairment

Germany, Bulgaria

3

Subscribe